A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
At a glance
- Drugs ABBV 176 (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Hepatocellular carcinoma; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 21 Jul 2017 Planned End Date changed from 9 Jul 2019 to 3 Sep 2019.
- 21 Jul 2017 Status changed from not yet recruiting to recruiting.
- 11 May 2017 New trial record